Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 18F- DCFPyL PET/CT Clear all
Completed No phase listed Observational

Multimodal Machine Learning Characterization of Solid Tumors

NCT04687969
View directory record Official record
Conditions
Adenocarcinoma of Prostate, Radical Prostatectomy, Hepatocellular Carcinoma (HCC), Glioma, Renal Cell Carcinoma (RCC), Prostate Cancer
Interventions
[18F]DCFPyL, PET/MRI scanner
Drug · Radiation
Lead sponsor
Ciprian Catana, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 3, 2026, 9:37 AM EDT
Recruiting Phase 2 Interventional

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

NCT06499870
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Enzalutamide, Fluorine F 18 Piflufolastat, Image Guided Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Relugolix
Procedure · Drug · Other + 1 more
Lead sponsor
Sean Sachdev
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 3, 2026, 9:37 AM EDT
Completed Phase 2 Interventional

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

NCT03860987
View directory record Official record
Conditions
Castrate Sensitive Prostate Cancer
Interventions
goserelin, Enzalutamide, Abiraterone, 18F-DCFPyL, Prednisone, Radical Prostatectomy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 3, 2026, 9:37 AM EDT
Terminated Phase 1 Interventional

Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy

NCT03619655
View directory record Official record
Conditions
Prostate Cancer
Interventions
SPECT CT, 18F-DCFPyL PET/CT, 18F-NaF PET/CT, WB-MRI
Procedure · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Sep 3, 2026, 9:37 AM EDT
Completed Phase 1 Interventional

Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer

NCT03793543
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL Injection
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 3, 2026, 9:37 AM EDT
Recruiting Early Phase 1 Interventional

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

NCT03861676
View directory record Official record
Conditions
Prostate Cancer
Interventions
Focal brachytherapy with PSMA PET imaging, (18F)DCFPyL
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 3, 2026, 9:37 AM EDT
Terminated Phase 2 Interventional Results available

Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies

NCT03387514
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
PSMA-based 18F-DCFPyL PET tracer for PET/CT exams
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 3, 2026, 9:37 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Ultralow Dose PET Imaging for PSMA Expression

NCT06904313
View directory record Official record
Conditions
Healthy Volunteer, Prostate CA
Interventions
Piflufolastat F18
Drug
Lead sponsor
Akiva Mintz
Other
Eligibility
18 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 3, 2026, 9:37 AM EDT
Completed Phase 2 Interventional Results available

18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer

NCT04390880
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older · Male only
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 3, 2026, 9:37 AM EDT
Recruiting Phase 2 Interventional

Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

NCT04573231
View directory record Official record
Conditions
Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
18F-DCFPyL
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 3, 2026, 9:37 AM EDT
Completed Phase 3 Interventional Results available

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

NCT03739684
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Recurrent, Prostate Cancer Metastatic
Interventions
18F-DCFPyL, PET/CT Imaging
Drug · Diagnostic Test
Lead sponsor
Progenics Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 3, 2026, 9:37 AM EDT
Active, not recruiting Phase 2 Interventional

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

NCT03976843
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
6
States / cities
New Orleans, Louisiana • Baltimore, Maryland • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 3, 2026, 9:37 AM EDT
Terminated Phase 2 Interventional Results available

18F-DCFPyL PET/CT in Hepatocellular Carcinoma

NCT05009979
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
F18-FDG, MRI, CT, F18-DCFPyL, Tumor biopsy
Drug · Device · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 3, 2026, 9:37 AM EDT
Active, not recruiting Phase 2 Interventional

18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

NCT03173924
View directory record Official record
Conditions
Metastatic Prostate Cancer, Prostatic Neoplasms, Prostate Cancer, Prostatic Cancer, Prostate Neoplasms
Interventions
18F-NaF, 18F-DCFPyL, 18F-FDG
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 3, 2026, 9:37 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

NCT02981368
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL Injection, PET/CT imaging
Drug · Diagnostic Test
Lead sponsor
Progenics Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2021 · Synced Sep 3, 2026, 9:37 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

NCT03800784
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL Injection
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 3, 2026, 9:37 AM EDT
Active, not recruiting No phase listed Observational

Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer

NCT04030338
View directory record Official record
Conditions
Prostate Cancer, Prostate Neoplasm, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Metastatic Prostate Cancer
Interventions
18F-DCFPyL-iPSMA, 68Ga-HBED-iPSMA, PET/CT scan
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 3, 2026, 9:37 AM EDT
Completed Phase 1 Interventional

Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET

NCT03542773
View directory record Official record
Conditions
Schwannomas, Malignant Tumors
Interventions
18F-DCFPyL Injection
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Sep 3, 2026, 9:37 AM EDT
Active, not recruiting Phase 1 Interventional

A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer

NCT05394259
View directory record Official record
Conditions
Pancreatic Cancer, Breast Cancer, Hepatocellular Carcinoma
Interventions
Piflufolastat F18
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 3, 2026, 9:37 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC

NCT07084909
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
piflufolastat F 18
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
St Louis, Missouri • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 3, 2026, 9:37 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer

NCT03824275
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
18F- DCFPyL PET/CT
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Sep 3, 2026, 9:37 AM EDT
Not listed Phase 2Phase 3 Interventional

18F-DCFPyL PET-CT Scan and Prostate Cancer

NCT03852654
View directory record Official record
Conditions
Prostate Cancer Adenocarcinoma
Interventions
18F-DCFPyL
Drug
Lead sponsor
Lida Jafari
Federal
Eligibility
18 Years and older · Male only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2019 · Synced Sep 3, 2026, 9:37 AM EDT
Completed Not applicable Interventional Results available

Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy

NCT02523924
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
18F-DCFPyL
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Sep 3, 2026, 9:37 AM EDT
Active, not recruiting Phase 2 Interventional

Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers

NCT03585114
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
[F-18] DCFPyL, PET/CT imaging
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Sep 3, 2026, 9:37 AM EDT